Ian E. Krop
- Oncology top 0.05%
- HER2/EGFR in Cancer Research 173
- Cancer Treatment and Pharmacology 114
- Cancer Research top 0.2%
- Breast Cancer Treatment Studies 63
- Cancer Genomics and Diagnostics 31
-
- Monoclonal and Polyclonal Antibodies Research 68
- Pulmonary and Respiratory Medicine top 0.2%
- Advanced Breast Cancer Therapies 87
- Lung Cancer Treatments and Mutations 32
- Genetics top 0.5%
-
- PI3K/AKT/mTOR signaling in cancer 30
Ian E. Krop
288 papers receiving 18.7k citations
Hit Papers
Peers
Comparison fields: 5 of 138
- Oncology 13.9k
- Cancer Research 4.0k
- Radiology, Nuclear Medicine and Imaging 5.7k
- Pulmonary and Respiratory Medicine 5.4k
- Genetics 1.6k
Countries citing papers authored by Ian E. Krop
This map shows the geographic impact of Ian E. Krop's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ian E. Krop with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ian E. Krop more than expected).
Fields of papers citing papers by Ian E. Krop
This network shows the impact of papers produced by Ian E. Krop. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ian E. Krop. The network helps show where Ian E. Krop may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Ian E. Krop, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 4 | |
| 2 | 2024 | 0 | |
| 3 | 2024 | 4 | |
| 4 | 2024 | 8 | |
| 5 | 2023 | 1 | |
| 6 | 2022 | 5 | |
| 7 | 2021 | 21 | |
| 8 | 2020 | 70 | |
| 9 | Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 studybreakdown → | 2019 | 258 |
| 10 | 2018 | 57 | |
| 11 | 2018 | 105 | |
| 12 | 2018 | 95 | |
| 13 | 2017 | 120 | |
| 14 | 2014 | 258 | |
| 15 | 2014 | 134 | |
| 16 | 2013 | 209 | |
| 17 | 2013 | 15 | |
| 18 | Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancerbreakdown → | 2012 | 2665 |
| 19 | 2011 | 106 | |
| 20 | 2008 | 80 |
About Ian E. Krop
Ian E. Krop is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine, having authored 298 papers that have together received 19.0k indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (173 papers), Cancer Treatment and Pharmacology (114 papers), Advanced Breast Cancer Therapies (87 papers), Monoclonal and Polyclonal Antibodies Research (68 papers), Breast Cancer Treatment Studies (63 papers), Lung Cancer Treatments and Mutations (32 papers), Cancer Genomics and Diagnostics (31 papers) and PI3K/AKT/mTOR signaling in cancer (30 papers). The work is most often cited by research in Oncology (13.9k citations), Cancer Research (4.0k citations) and Radiology, Nuclear Medicine and Imaging (5.7k citations). Ian E. Krop has collaborated with scholars based in United States, Spain and France. Frequent co-authors include Eric P. Winer, Véronique Dièras, David Miles, Manfred Welslau, Sunil Verma, Ellie Guardino, Mark D. Pegram, Luca Gianni, Kim T. Blackwell and Michael W. Lu. Their work appears in journals such as Journal of Clinical Oncology, Cancer Research, Annals of Oncology, Clinical Cancer Research and Breast Cancer Research and Treatment.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.